Fig. 4: Responders decrease immunosuppressive cells in the TME. | Nature Cancer

Fig. 4: Responders decrease immunosuppressive cells in the TME.

From: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

Fig. 4: Responders decrease immunosuppressive cells in the TME.The alt text for this image may have been generated using AI.

a, VECTRA image quantification of Treg cells (CD3+CD8−Foxp3+) in patient tumors pre- and post-treatment (nonresponders n = 5, responders n = 7). Nonresponders P = 0.84 and responders P = 0.03. b, Ratio of CD8+ T cells (CD3+CD8+) to Treg cells in the TME pre- and post-treatment (nonresponders n = 5 patients, responders n = 7 patients). Nonresponders P = 0.28 and responders P = 0.0032. c, Representative VECTRA image of the TME pre- and post-treatment. Patients 01-002 and 01-007 representing two different kinds of non-responders to treatment. To the right, CD8+ T cells (red) and Treg cells (blue) are highlighted. d, VECTRA quantification of the distance between Treg cells and DCs (CD209+) in the TME of responders and nonresponders pre- and post-treatment (nonresponders n = 5 patients, responders n = 7 patients). Nonresponders P = 0.38 and responders P = 0.0024. e, MultiPLIER quantification of LV57 (nonresponders n = 5, responders n = 8). Nonresponders P = 0.0006 and responders P = 0.99. Statistical significance was determined using a two-tailed paired student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001.

Source data

Back to article page